First Citizens Bank & Trust Co. Has $10.95 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First Citizens Bank & Trust Co. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 17.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,563 shares of the company’s stock after selling 15,541 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of First Citizens Bank & Trust Co.’s holdings, making the stock its 21st biggest holding. First Citizens Bank & Trust Co.’s holdings in Johnson & Johnson were worth $10,952,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in JNJ. BlackRock Inc. increased its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after purchasing an additional 1,168,129 shares in the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 0.3% during the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Johnson & Johnson by 88.0% during the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after purchasing an additional 8,062,204 shares in the last quarter. Swiss National Bank increased its position in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Swiss National Bank now owns 11,304,866 shares of the company’s stock worth $1,589,803,000 after purchasing an additional 157,100 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. California Public Employees Retirement System now owns 9,752,233 shares of the company’s stock worth $1,371,457,000 after purchasing an additional 210,973 shares in the last quarter. Institutional investors own 67.44% of the company’s stock.

JNJ has been the subject of a number of recent analyst reports. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $161.00 to $164.00 in a research report on Monday, July 20th. Raymond James increased their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective on the stock. in a report on Tuesday, July 7th. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $164.93.

Shares of NYSE JNJ opened at $148.10 on Friday. The firm has a market capitalization of $389.92 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The firm’s 50-day moving average is $148.57 and its 200-day moving average is $146.59.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.12 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 8 earnings per share for the current fiscal year.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: Liquidity

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.